Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

02.10.14		Susheel Surpal Steps Down as Executive Vice President, Chief Financial Officer of Ipsen to Pursue Other Opportunities (Businesswire)
27.09.14		Ipsen Presents Preliminary Results of Exploratory Proof-of-Concept Study with Tasquinimod in Four Advanced Tumor Types at the ESMO 2014 Congress (Businesswire)
04.09.14		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.09.14		Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NET1s in the US with Priority Review and in Europe (Businesswire)
29.08.14		Ipsen: 2014 Half-Year Results and 2014 Objectives (Businesswire)
06.08.14		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.08.14		Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
17.07.14		New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors (Businesswire)
11.07.14		Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1 (Businesswire)
08.07.14		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.07.14		Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (Businesswire)
05.06.14		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.06.14		Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014 (Businesswire)
13.05.14		Ipsen SA: Ordinary Shareholders’ Meeting of 4 June 2014 (Businesswire)
13.05.14		Ipsen Announces a Step Forward in the Resupply of Increlex® in the U.S. (Businesswire)
07.05.14		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
30.04.14		Ipsen’s first quarter 2014 sales (Businesswire)
29.04.14		Ipsen: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to the Approval of the Ordinary Shareholders’ Meeting to Be Held on 4 June 2014 (Businesswire)
09.04.14		Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext (Businesswire)
20.03.14		Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement (Businesswire)
18.03.14		Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO) (Businesswire)
10.03.14		CORRECTING and REPLACING: Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
10.03.14		CORRECTING and REPLACING: Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
28.02.14		Ipsen's 2013 results and 2014 financial objectives (Businesswire)
07.02.14		Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer (Businesswire)
05.02.14		Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW1 (Businesswire)
28.01.14		Ipsen: sales in the fourth quarter and full year 2013 (Businesswire)
22.01.14		Ipsen Implements a New Governance in the United States to Prepare for the Launch of Somatuline® in Oncology (Businesswire)
17.01.14		Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint (Businesswire)
14.01.14		Ipsen and GW Pharmaceuticals plc Enter into Agreement for Ipsen to Promote and Distribute Sativex® in Latin America (Businesswire)
14.01.14		Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors (Businesswire)
13.01.14		Half-year IPSEN Liquidity Contract Statement Entered into With NATIXIS (Businesswire)
10.01.14		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
10.01.14		Jonathan Barnsley Joins Ipsen as Executive Vice President, Technical Operations (Businesswire)
23.12.13		Ipsen Announces Its Corporate Agenda for 2014 (Businesswire)
18.12.13		Ipsen and Mayoly Spindler enter into cross- promotion agreement for primary care activities in France (Businesswire)
18.12.13		Ipsen Prepares for the Resupply of Increlex® in Europe (Businesswire)
17.12.13		Ipsen Announces Positive Initial Results from the International Double-Blind Clinical Phase III Study of Dysport® in the Treatment of Adults Suffering from Upper Limb Spasticity (Businesswire)
12.12.13		Dominique Brard Joins Ipsen as Executive Vice President, Human Resources (Businesswire)
09.12.13		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.11.13		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.11.13		Ipsen Initiates a Share Buy-Back Program to Partially Cover Its Restricted Share Plans (Businesswire)
30.10.13		Ipsen: Sales in the Third Quarter and First Nine Months of 2013 (Businesswire)
09.10.13		Active Biotech Receives Tasquinimod Milestone Payment from Ipsen for 10TASQ10 Study (Businesswire)
07.10.13		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.10.13		PeptiDream and Ipsen Expand the Scope of Their Collaboration for Discovery of Peptide Drugs to Treat Serious Endocrinologic Disease (Businesswire)
02.10.13		Project of New Organization and New Composition of the Executive Committee to Accelerate the Implementation of Ipsen's Strategy (Businesswire)
28.09.13		Ipsen : results from CLARINET® Phase III clinical trial showed the antiproliferative effect of Somatuline® in the treatment of non-functioning GEP-NETs (Businesswire)
26.09.13		Ipsen to Relocate US R&D Activities to Cambridge, MA in 2014 (Businesswire)
26.09.13		Ipsen to Relocate US R&D Activities to Cambridge, MA in 2014 (Businesswire)

Erste Seite Zurück | ... | 6 | 7 | 8 | 9 | Weiter

Newssuche

Meistgelesene Nachrichten

Wall Street-Analysten sagen Rekordwachstum voraus - diese Unternehmen werden am meisten profitieren

Intel rüstet sich für den Wettbewerb gegen NVIDIA & Co.: Diese Pläne sollen den Marktanteil sichern

Pierer Mobility-Aktie dreht ins Minus: KTM-Mutter Pierer Mobility-Aktionäre stimmen für Kapitalerhöhung

STRABAG-Urteil - RBI: Aktienpaket könnte versteigert werden - Gewinnprognose angehoben - Aktien höher

APA - N A C H R I C H T E N Ü B E R B L I C K

Bitcoin, Ether & Co. in der vergangenen Woche: Wochenbilanz der Kryptowährungen in KW 4

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	28.01.2025 22:16
Kaufwert:	EUR
	Hinzufügen Speichern